Celon Pharma

Celon Pharma Quick Ratio

The Quick Ratio (Acid Test) of Celon Pharma (CLN.WA) as of Oct 27, 2026 is 0.38. In the previous year, Quick Ratio (Acid Test) was 1.08 — a change of -64.75% (lower).

Quick Ratio

0.38

YoY

-64.75%

Last updated:

Quick Ratio (Acid Test) of Celon Pharma is 2025 0.38 . Quick Ratio (Acid Test) of Celon Pharma was 2024 1.08 . It decreases by -64.75% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celon Pharma Stock analysis

What does Celon Pharma do? Celon Pharma SA develops and manufactures generic drugs for cancer, neurological diseases, diabetes, and metabolic disorders. Its product portfolio includes pills like Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder Salmex. The company operates through its research center focused on oncology, neurology, and inflammatory and metabolic diseases. As a subsidiary of Glatton sp z o o, Celon Pharma SA serves healthcare providers and patients seeking affordable treatment options for chronic conditions. Celon Pharma SA's revenue comes from selling its generic drug portfolio to pharmacies, hospitals, and healthcare institutions. The firm's products target patients with conditions such as cancer, neurological disorders, and diabetes, where cost-effective alternatives are in demand. Glatton sp z o o, the parent company, likely oversees strategic direction and resource allocation for Celon Pharma SA's operations. The company's focus on generic drugs positions it within the pharmaceutical market segment for affordable treatments. Its research center develops new formulations within therapeutic areas like oncology and neurology, supporting ongoing product innovation. Celon Pharma SA's product lineup, including inhalation powder Salmex and pill-based treatments, caters to specific medical needs across multiple disease categories. Celon Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celon Pharma stock

Quick Ratio (Acid Test) of Celon Pharma is 0.38 in 2025.

Quick Ratio (Acid Test) of Celon Pharma changed from 1.08 to 0.38, representing a -64.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Celon Pharma since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Celon Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Celon Pharma

All Key Metrics — Celon Pharma